Your browser doesn't support javascript.
loading
Idelalisib immune-related toxicity is associated with improved treatment response.
Wagner-Johnston, Nina D; Sharman, Jeff; Furman, Richard R; Salles, Gilles; Brown, Jennifer R; Robak, Tadeusz; Gu, Lin; Xing, Guan; Chan, Rebecca J; Rajakumaraswamy, Nishanthan; Gopal, Ajay K.
Afiliación
  • Wagner-Johnston ND; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Sharman J; US Oncology, Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.
  • Furman RR; Weill Cornell Medicine, New York, NY, USA.
  • Salles G; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Brown JR; CLL Center, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Robak T; Medical University of Lodz, Lodz, Poland.
  • Gu L; Gilead Sciences, Inc, Foster City, CA, USA.
  • Xing G; Gilead Sciences, Inc, Foster City, CA, USA.
  • Chan RJ; Gilead Sciences, Inc, Foster City, CA, USA.
  • Rajakumaraswamy N; Gilead Sciences, Inc, Foster City, CA, USA.
  • Gopal AK; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Leuk Lymphoma ; 62(12): 2915-2920, 2021 12.
Article en En | MEDLINE | ID: mdl-34319205
Idelalisib is associated with increased occurrence of immune-related adverse events (irAEs). Clinical observations suggest a correlation between immune checkpoint inhibitor-induced irAEs and survival outcomes in patients with solid tumors; however, this relationship in hematologic malignancies is not well understood. In a post hoc analysis of 3 registrational trials, we explored the relationship between Grade ≥3 diarrhea/colitis and alanine/aspartate transaminase (ALT/AST) elevation incidences and efficacy endpoints in patients with indolent non-Hodgkin lymphoma (iNHL), follicular lymphoma (FL), and chronic lymphocytic leukemia treated with idelalisib. Grade ≥3 diarrhea/colitis was associated with higher overall response rate (ORR) and longer progression-free survival (PFS) for all subgroups. Grade ≥3 ALT/AST elevations were associated with improved duration of response and overall survival for all subgroups and improved ORR and PFS for patients with FL or iNHL. Our analysis in hematologic malignancies showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Leucemia Linfocítica Crónica de Células B / Linfoma Folicular / Colitis / Neoplasias Hematológicas Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Leucemia Linfocítica Crónica de Células B / Linfoma Folicular / Colitis / Neoplasias Hematológicas Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos